Relapse and leukemia-free survival rates after allogeneic PBSCT or BMT
| Study . | Relapse rate . | Disease-free survival rate (overall survival rate) . | ||
|---|---|---|---|---|
| BM (%) . | PBSC (%) . | BM (%) . | PBSC (%) . | |
| Vigorito et al38 | 10.5 (median FU, 631 d) | 11 (median FU, 335 d) | 52 (at 1000 d) | 58 (at 1000 d) |
| Blaise et al39 | 9 (median FU, 20 mo) | 9 (median FU, 20 mo) | 66 (at 2 y) | 67 (at 2 y) |
| Ringden et al40 | 38 (1-y probability) | 34 (1-y probability) | 48 overall | 46 overall |
| 70 (low risk) | 63 (low risk) | |||
| 33 (high risk) | 31 (high risk) | |||
| (at 1 y) | (at 1 y) | |||
| Heldal et al41 | 30 (median FU, 36 mo) | 3.2 (median FU, 34 mo) | NA | NA |
| Powles et al42 | 376-150 (2-y probability) | 06-150 (2-y probability) | NA | NA |
| Schmitz et al43 | No significant difference | No significant difference | No significant difference | No significant difference |
| Simpson et al44 | NA | NA | (55 [at 2 y])6-150 | (68 [at 2 y])6-150 |
| Champlin et al45 | 11 AL CR1 | 14 AL CR1 | 61 AL CR1 | 70 AL CR1 |
| 13 AL CR2 | 8 AL CR2 | 57 AL CR26-150 | 77 AL CR26-150 | |
| 1 CML CP1 | 2 CML CP1 | 74 CML CP1 | 63 CML CP1 | |
| 21 CML AP | 13 CML AP | 23 CML AP6-150 | 68 CML AP6-150 | |
| (1-y probability) | (1-y probability) | (1-y probability) | (1-y probability) | |
| Bensinger et al10 | 25 (at 2 y) | 14 (at 2 y) | 45 overall6-150 | 65 overall6-150 |
| 72 (less advanced cancer) | 75 (less advanced cancer) | |||
| 336-150 (more advanced cancer) | 576-150(more advanced cancer) | |||
| (at 2 y) | (at 2 y) | |||
| (54 [at 2 y])6-150 | (66 [at 2 y])6-150 | |||
| Study . | Relapse rate . | Disease-free survival rate (overall survival rate) . | ||
|---|---|---|---|---|
| BM (%) . | PBSC (%) . | BM (%) . | PBSC (%) . | |
| Vigorito et al38 | 10.5 (median FU, 631 d) | 11 (median FU, 335 d) | 52 (at 1000 d) | 58 (at 1000 d) |
| Blaise et al39 | 9 (median FU, 20 mo) | 9 (median FU, 20 mo) | 66 (at 2 y) | 67 (at 2 y) |
| Ringden et al40 | 38 (1-y probability) | 34 (1-y probability) | 48 overall | 46 overall |
| 70 (low risk) | 63 (low risk) | |||
| 33 (high risk) | 31 (high risk) | |||
| (at 1 y) | (at 1 y) | |||
| Heldal et al41 | 30 (median FU, 36 mo) | 3.2 (median FU, 34 mo) | NA | NA |
| Powles et al42 | 376-150 (2-y probability) | 06-150 (2-y probability) | NA | NA |
| Schmitz et al43 | No significant difference | No significant difference | No significant difference | No significant difference |
| Simpson et al44 | NA | NA | (55 [at 2 y])6-150 | (68 [at 2 y])6-150 |
| Champlin et al45 | 11 AL CR1 | 14 AL CR1 | 61 AL CR1 | 70 AL CR1 |
| 13 AL CR2 | 8 AL CR2 | 57 AL CR26-150 | 77 AL CR26-150 | |
| 1 CML CP1 | 2 CML CP1 | 74 CML CP1 | 63 CML CP1 | |
| 21 CML AP | 13 CML AP | 23 CML AP6-150 | 68 CML AP6-150 | |
| (1-y probability) | (1-y probability) | (1-y probability) | (1-y probability) | |
| Bensinger et al10 | 25 (at 2 y) | 14 (at 2 y) | 45 overall6-150 | 65 overall6-150 |
| 72 (less advanced cancer) | 75 (less advanced cancer) | |||
| 336-150 (more advanced cancer) | 576-150(more advanced cancer) | |||
| (at 2 y) | (at 2 y) | |||
| (54 [at 2 y])6-150 | (66 [at 2 y])6-150 | |||
Abbreviations are explained in Tables 4 and 5.
Statistical significance.